| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHCHD7 |
| Uniprot No | Q9BUK0-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMHQTRTG KKTVRMPSVT QRLRDPDINP CLSESDASTR CLDENNYDRE RCSTYFLRYK NCRRFWNSIV MQRRKNGVKP FMPTAAERDE ILRAVGNMPY |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下提供的参考文献为示例性内容，基于CHCHD7相关研究的常见方向模拟生成，非真实存在的论文，仅供格式参考：
1. **文献名称**：*Structural and functional characterization of CHCHD7 recombinant protein in mitochondrial metabolism*
**作者**：Zhang L, et al.
**摘要**：本研究通过重组表达纯化获得人源CHCHD7蛋白，解析其晶体结构，揭示其通过保守的CHCH结构域参与线粒体内膜复合物组装，调控细胞氧化磷酸化功能。
2. **文献名称**：*CHCHD7 interacts with OPA1 to regulate mitochondrial fusion and apoptosis*
**作者**：Wang Y, et al.
**摘要**：首次报道CHCHD7重组蛋白与线粒体动态蛋白OPA1的相互作用，证明其在过表达条件下抑制线粒体分裂并减少细胞凋亡，提示其在神经退行性疾病中的潜在作用。
3. **文献名称**：*Recombinant CHCHD7 as a biomarker in thyroid cancer progression*
**作者**：Kim S, et al.
**摘要**：通过制备高纯度CHCHD7重组蛋白，开发特异性抗体，发现其在甲状腺癌组织中异常高表达，且与患者预后不良相关，为癌症诊断提供新靶点。
---
**备注**：若需真实文献，建议通过PubMed或Web of Science以关键词“CHCHD7 recombinant protein”或“CHCHD7 mitochondrial function”检索，并筛选近年高影响力期刊论文。CHCHD7的研究目前多集中于其在线粒体结构、癌症代谢及与CHCHD家族蛋白(如CHCHD4)的互作机制。
**Background of CHCHD7 Recombinant Protein**
CHCHD7 (Coiled-coil-helix-coiled-coil-helix domain-containing protein 7) is a member of the CHCHD protein family, characterized by tandem CHCH (coiled-coil-helix-coiled-coil-helix) domains. These domains facilitate protein-protein interactions and mitochondrial localization. CHCHD7 is primarily localized to the mitochondria and nucleus, where it plays roles in mitochondrial structure, energy metabolism, and cellular stress responses. Studies suggest its involvement in regulating oxidative phosphorylation, apoptosis, and mitochondrial dynamics, linking it to cellular homeostasis and disease pathogenesis.
Recombinant CHCHD7 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, functional protein for *in vitro* studies. This tool enables researchers to investigate CHCHD7’s molecular interactions, post-translational modifications, and structural properties. For instance, recombinant CHCHD7 has been utilized to study its binding partners, such as members of the mitochondrial electron transport chain or nuclear transcription factors, highlighting its dual role in mitochondrial and genomic regulation.
Interest in CHCHD7 has grown due to its association with diseases, including cancer, neurodegenerative disorders (e.g., Alzheimer’s), and cardiovascular conditions. Dysregulation of CHCHD7 correlates with mitochondrial dysfunction, a hallmark of many age-related diseases. Recombinant protein studies are critical for mapping functional domains, analyzing disease-linked mutations (e.g., those affecting mitochondrial morphology), and screening therapeutic compounds targeting CHCHD7 pathways.
Despite progress, challenges remain in understanding CHCHD7’s precise mechanisms, particularly its nuclear-mitochondrial crosstalk. Recombinant CHCHD7 provides a versatile platform to address these gaps, offering insights into its role as a potential biomarker or therapeutic target in mitochondrial disorders.
×
